Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase

Molecular Endocrinology

Volumn 21, Issue 10, 2007, Pages 2579-2595

  Pandey, Amit V ^a   Kempna, Petra ^a   Hofer, Gaby ^a   Mullis, Primus E ^a   Flück, Christa E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; AROMATASE; CYTOCHROME P450 CYP19A1; OCTANOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEOMICS; STEROIDOGENESIS;

AROMATASE; BINDING SITES; ELECTRON TRANSPORT; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, MOLECULAR; MUTATION; NADPH-FERRIHEMOPROTEIN REDUCTASE; POTASSIUM CHLORIDE; PROTEIN STRUCTURE, TERTIARY; STEROID 17-ALPHA-HYDROXYLASE;

EID: 34948830894     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0245     Document Type: Article

References (90)

1. Shephard EA, Phillips IR, Santisteban I, West LF, Palmer CN, Ashworth A, Povey S 1989 Isolation of a human cytochrome P-450 reductase cDNA clone and localization of the corresponding gene to chromosome 7q11.2. Ann Hum Genet 53:291-301
2. Scott RR, Gomes LG, Huang N, Van Vliet G, Miller WL 2007 Apparent manifesting heterozygosity in p450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J Clin Endocrinol Metab 92:2318-2322
3. Haniu M, McManus ME, Birkett DJ, Lee TD, Shively JE 1989 Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites. Biochemistry 28:8639-8645
4. Horecker BL, Heppel LA 1949 The reduction of cytochrome c by xanthine oxidase. J Biol Chem 178:683-690
5. Horecker BL 1950 Triphosphate nucleotide-cytochrome c reductase in liver. J Biol Chem 183:593-605
6. Williams Jr CH, Kamin H 1962 Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J Biol Chem 237:587-595
7. Phillips AH, Langdon RG 1962 Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J Biol Chem 237:2652-2660
8. Lu AY, Junk KW, Coon MJ 1969 Resolution of the cytochrome P-450-containing ω-hydroxylation system of liver microsomes into three components. J Biol Chem 244:3714-3721
9. Wang M, Roberts DL, Paschke R, Shea TM, Masters BSS, Kim JJ 1997 Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci USA 94:8411-8416
10. Zhao Q, Modi S, Smith G, Paine M, McDonagh PD, Wolf CR, Tew D, Lian LY, Roberts GC, Driessen HP 1999 Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 A resolution. Protein Sci 8:298-306
11. Roman LJ, McLain J, Masters BSS 2003 Chimeric enzymes of cytochrome P450 oxidoreductase and neuronal nitric-oxide synthase reductase domain reveal structural and functional differences. J Biol Chem 278:25700-25707
12. Munro AW, Noble MA, Robledo L, Daff SN, Chapman SK 2001 Determination of the redox properties of human NADPH-cytochrome P450 reductase. Biochemistry 40:1956-1963
13. Hubbard PA, Shen AL, Paschke R, Kasper CB, Kim JJ 2001 NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J Biol Chem 276:29163-29170
14. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW 2004 Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18
15. Miller WL 2005 Minireview: regulation of steroidogenesis by electron transfer. Endocrinology 146:2544-2550
16. Shen AL, O'Leary KA, Kasper CB 2002 Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 277:6536-6541
17. Otto DM, Henderson CJ, Carrie D, Davey M, Gundersen TE, Blomhoff R, Adams RH, Tickle C, Wolf CR 2003 Identification of novel roles of the cytochrome P450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 23:6103-6116
18. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonca BB, Fujieda K, Miller WL 2004 Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 36:228-230
19. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Flück CE, Miller WL 2005 Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 76:729-749
20. Pandey AV, Flück CE, Huang N, Tajima T, Fujieda K, Miller WL 2004 P450 oxidoreductase deficiency: a new disorder of steroidogenesis affecting all microsomal P450 enzymes. Endocr Res 30:881-888
21. Pandey AV 2006 Biochemical analysis of mutations in P450 oxidoreductase. Biochem Soc Trans 34:1186-1191
22. Miller WL 2004 P450 oxidoreductase deficiency: a new disorder of steroidogenesis with multiple clinical manifestations. Trends Endocrinol Metab 15:311-315
23. Miller WL, Huang N, Flück CE, Pandey AV 2004 P450 oxidoreductase deficiency. Lancet 364:1663
24. Miller WL, Huang N, Pandey AV, Flück CE, Agrawal V 2005 P450 oxidoreductase deficiency: a new disorder of steroidogenesis. Ann NY Acad Sci 1061:100-108
25. Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder SM, Borucka-Mankiewicz M, Hauffa BP, Malunowicz EM, Stewart PM, Shackleton CH 2004 Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 363:2128-2135
26. Adachi M, Tachibana K, Asakura Y, Yamamoto T, Hanaki K, Oka A 2004 Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am J Med Genet 128A:333-339
27. Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, Sato N, Okuyama T, Nakai H, Soneda S, Tachibana K, Matsuo N, Sato S, Homma K, Nishimura G, Hasegawa T, Ogata T 2005 Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 90:414-426
28. Adachi M, Asakura Y, Matsuo M, Yamamoto T, Hanaki K, Arlt W 2006 POR R457H is a global founder mutation causing Antley-Bixler syndrome with autosomal recessive trait. Am J Med Genet A 140:633-635
29. Homma K, Hasegawa T, Nagai T, Adachi M, Horikawa R, Fujiwara I, Tajima T, Takeda R, Fukami M, Ogata T 2006 Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J Clin Endocrinol Metab 91:2643-2649
30. Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T 2006 Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res 59:276-280
31. Haiman CA, Setiawan VW, Xia LY, Le Marchand L, Ingles SA, Ursin G, Press MF, Bernstein L, John EM, Henderson BE 2007 A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans. Cancer Res 67:3565-3568
32. Miller WL 1988 Molecular biology of steroid hormone synthesis. Endocr Rev 9:295-318
33. Simpson ER 2004 Aromatase: biologic relevance of tissue-specific expression. Semin Reprod Med 22:11-23
34. Nebert DW, Nelson DR, Feyereisen R 1989 Evolution of the cytochrome P450 genes. Xenobiotica 19:1149-1160
35. Pompon D, Perret A, Bellamine A, Laine R, Gautier JC, Urban P 1995 Genetically engineered yeast cells and their applications. Toxicol Lett 82-83:815-822
36. Lephart ED, Simpson ER 1991 Assay of aromatase activity. In: Waterman MR, Johnson EF, eds. Methods in enzymology. San Diego: Academic Press; 477-483
37. Auchus RJ, Lee TC, Miller WL 1998 Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 273:3158-3165
38. Reed JR, Kelley RW, Backes WL 2006 An evaluation of methods for the reconstitution of cytochromes P450 and NADPH P450 reductase into lipid vesicles. Drug Metab Dispos 34:660-666
39. Amarneh B, Simpson ER 1995 Expression of a recombinant derivative of human aromatase P450 in insect cells utilizing the baculovirus vector system. Mol Cell Endocrinol 109:R1-R5
40. Kagawa N, Hori H, Waterman MR, Yoshioka S 2004 Characterization of stable human aromatase expressed in E. coli. Steroids 69:235-243
41. Flück CE, Nicolo C, Pandey AV 2007 Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fundam Clin Pharmacol 21:399-410
42. Shen AL, Kasper CB 2000 Differential contributions of NADPH-cytochrome P450 oxidoreductase FAD binding site residues to flavin binding and catalysis. J Biol Chem 275:41087-41091
43. Shen AL, Kasper CB 1996 Role of Ser457 of NADPH-cytochrome P450 oxidoreductase in catalysis and control of FAD oxidation-reduction potential. Biochemistry 35:9451-9459
44. Shen AL, Sem DS, Kasper CB 1999 Mechanistic studies on the reductive half-reaction of NADPH-cytochrome P450 oxidoreductase. J Biol Chem 274:5391-5398
45. Marohnic CC, Panda SP, Martasek P, Masters BS 2006 Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J Biol Chem 281:35975-35982
46. Graham-Lorence S, Khalil MW, Lorence MC, Mendelson CR, Simpson ER 1991 Structure-function relationships of human aromatase cytochrome P-450 using molecular modeling and site-directed mutagenesis. J Biol Chem 266:11939-11946
47. Graham-Lorence S, Amarneh B, White RE, Peterson JA, Simpson ER 1995 A three-dimensional model of aromatase cytochrome P450. Protein Sci 4:1065-1080
48. Loge C, Le Borgne M, Marchand P, Robert JM, Le Baut G, Palzer M, Hartmann RW 2005 Three-dimensional model of cytochrome P450 human aromatase. J Enzyme Inhib Med Chem 20:581-585
49. Favia AD, Cavalli A, Masetti M, Carotti A, Recanatini M 2006 Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins 62:1074-1087
50. Auchus RJ, Miller WL 1999 Molecular modeling of human P450c17 (17α-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol Endocrinol 13:1169-1182
51. Monno S, Ogawa H, Date T, Fujioka M, Miller WL, Kobayashi M 1993 Mutation of histidine 373 to leucine in cytochrome P450c17 causes 17 α-hydroxylase deficiency. J Biol Chem 268:25811-25817
52. Janner M, Pandey AV, Mullis PE, Fluck CE 2006 Clinical and biochemical description of a novel CYP21A2 gene mutation 962_963insA using a new 3D model for the P450c21 protein. Eur J Endocrinol 155:143-151
53. Hanukoglu I, Gutfinger T 1989 cDNA sequence of adrenodoxin reductase. Identification of NADP-binding sites in oxidoreductases. Eur J Biochem 180:479-484
54. Scrutton NS, Berry A, Perham RN 1990 Redesign of the coenzyme specificity of a dehydrogenase by protein engineering. Nature 343:38-43
55. Shen AL, Christensen MJ, Kasper CB 1991 NADPH-cytochrome P-450 oxidoreductase. The role of cysteine 566 in catalysis and cofactor binding. J Biol Chem 266:19976-19980
56. Haniu M, Iyanagi T, Legesse K, Shively JE 1984 Structural analysis of NADPH-cytochrome P-450 reductase from porcine hepatic microsomes. Sequences of proteolytic fragments, cysteine-containing peptides, and a NADPH-protected cysteine peptide. J Biol Chem 259:13703-13711
57. Grogan J, Shou M, Zhou D, Chen S, Korzekwa KR 1993 Use of aromatase (CYP19) metabolite ratios to characterize electron transfer from NADPH-cytochrome P450 reductase. Biochemistry 32:12007-12012
58. Backes WL, Kelley RW 2003 Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes. Pharmacol Ther 98:221-233
59. Shen AL, Kasper CB 1995 Role of acidic residues in the interaction of NADPH-cytochrome P450 oxidoreductase with cytochrome P450 and cytochrome c. J Biol Chem 270:27475-27480
60. Estabrook RW, Shet MS, Fisher CW, Jenkins CM, Waterman MR 1996 The interaction of NADPH-P450 reductase with P450: an electrochemical study of the role of the flavin mononucleotide-binding domain. Arch Biochem Biophys 333:308-315
61. Hasemann CA, Kurumbail RG, Boddupalli SS, Peterson JA, Deisenhofer J 1995 Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 3:41-62
62. Fisher CW, Shet MS, Estabrook RW 1996 Construction of plasmids and expression in Escherichia coli of enzymatically active fusion proteins containing the heme-domain of a P450 linked to NADPH-P450 reductase. Methods Enzymol 272:15-25
63. Davydov DR, Kariakin AA, Petushkova NA, Peterson JA 2000 Association of cytochromes P450 with their reductases: opposite sign of the electrostatic interactions in P450BM-3 as compared with the microsomal 2B4 system. Biochemistry 39:6489-6497
64. Nadler SG, Strobel HW 1991 Identification and characterization of an NADPH-cytochrome P450 reductase derived peptide involved in binding to cytochrome P450. Arch Biochem Biophys 290:277-284
65. Shen S, Strobel HW 1993 Role of lysine and arginine residues of cytochrome P450 in the interaction between cytochrome P4502B1 and NADPH-cytochrome P450 reductase. Arch Biochem Biophys 304:257-265
66. Shen S, Strobel HW 1992 The role of cytochrome P450 lysine residues in the interaction between cytochrome P450IA1 and NADPH-cytochrome P450 reductase. Arch Biochem Biophys 294:83-90
67. Shimizu T, Tateishi T, Hatano M, Fujii-Kuriyama Y 1991 Probing the role of lysines and arginines in the catalytic function of cytochrome P450d by site-directed mutagen-esis. Interaction with NADPH-cytochrome P450 reductase. J Biol Chem 266:3372-3375
68. Nadler SG, Strobel HW 1988 Role of electrostatic interactions in the reaction of NADPH-cytochrome P-450 reductase with cytochromes P-450. Arch Biochem Biophys 261:418-429
69. Strobel HW, Nadler SG, Nelson DR 1989 Cytochrome P-450: cytochrome P-450 reductase interactions. Drug Metab Rev 20:519-533
70. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, Simpson ER, Carani C 2004 Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 89:61-70
71. Pompon D, Louerat B, Bronine A, Urban P 1996 Yeast expression of animal and plant P450s in optimized redox environments. Methods Enzymol 272:51-64
72. Urban P, Truan G, Gautier JC, Pompon D 1993 Xenobiotic metabolism in humanized yeast: engineered yeast cells producing human NADPH-cytochrome P-450 reductase, cytochrome b5, epoxide hydrolase and P-450s. Biochem Soc Trans 21:1028-1034
73. Harada N 1988 Novel properties of human placental aromatase as cytochrome P-450: purification and characterization of a unique form of aromatase. J Biochem (Tokyo) 103:106-133
74. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF 2004 The structure of human microsomal cytochrome P450 3A4 determined by x-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091-38094
75. Scott EE, White MA, He YA, Johnson EF, Stout CD, Halpert JR 2004 Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl) imidazole at 1.9-A resolution: insight into the range of P450 conformations and the coordination of redox partner binding. J Biol Chem 279:27294-27301
76. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, Thompson JD 2003 Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31:3497-3500
77. Sali A, Blundell TL 1993 Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815
78. Hooft RW, Vriend G, Sander C, Abola EE 1996 Errors in protein structures. Nature 381:272
79. Eisenberg D, Luthy R, Bowie JU 1997 VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol 277:396-404
80. Morris AL, MacArthur MW, Hutchinson EG, Thornton JM 1992 Stereochemical quality of protein structure coordinates. Proteins 12:345-364
81. Ramachandran GN, Ramakrishnan C, Sasisekharan V 1963 Stereochemistry of polypeptide chain configurations. J Mol Biol 7:95-99
82. Hooft RW, Sander C, Vriend G 1997 Objectively judging the quality of a protein structure from a Ramachandran plot. Comput Appl Biosci 13:425-430
83. Holm L, Park J 2000 DaliLite workbench for protein structure comparison. Bioinformatics 16:566-567
84. Guex N, Peitsch MC 1997 SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18:2714-2723
85. Vriend G 1990 WHAT IF: a molecular modeling and drug design program. J Mol Graph 8:52- 56:29
86. Krieger E, Darden T, Nabuurs SB, Finkelstein A, Vriend G 2004 Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins 57:678-683
87. Liu H, Elstner M, Kaxiras E, Frauenheim T, Hermans J, Yang W 2001 Quantum mechanics simulation of protein dynamics on long timescale. Proteins 44:484-489
88. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, Chenery RJ, Bridges AM 2006 Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614-7622
89. Schneidman-Duhovny D, Inbar Y, Polak V, Shatsky M, Halperin I, Benyamini H, Barzilai A, Dror O, Haspel N, Nussinov R, Wolfson HJ 2003 Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking. Proteins 52:107-112
90. Mustard D, Ritchie DW 2005 Docking essential dynamics eigenstructures. Proteins 60:269-274